Overview: West Nile IgM TestIntroduction: The West Nile IgM Test detects West Nile virus IgM to diagnose recent infection, causing fever or headache. Aligned with 2023 CDC guidelines, it uses immunoassays for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected recent West Nile virus infection. Note: Test Parameters are not specified in input data; typically includes West Nile virus IgM antibodies.
Other Names: West Nile IgM Assay, WNV Acute Infection Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: West Nile IgM testing began in the 2000s with arbovirus research. Immunoassay methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects West Nile IgM to diagnose recent infection, guides treatment, and evaluates patients with fever or headache.
Test Parameters: Not specified in input data; typically includes West Nile virus IgM antibodies.
Pretest Condition: No fasting required. Collect serum, CSF, or saliva. Report history of fever, headache, or West Nile virus exposure.
Specimen: Serum (SST, 2-5 mL), CSF (sterile container, 1-2 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, headache, or history of West Nile virus exposure. Include current medications or travel history.
Consent: Written consent required, detailing the tests purpose, West Nile virus infection implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect West Nile IgM antibodies. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for acute infection diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Early infection may reduce sensitivity.
Clinical Significance: Positive West Nile IgM confirms recent infection, guiding supportive therapy or neurological monitoring. Negative results may require PCR or repeat testing.
Specialist Consultation: Consult an infectious disease specialist or neurologist for result interpretation and treatment planning.
Additional Supporting Tests: West Nile PCR, IgG, or neurological imaging to confirm acute infection diagnosis.
Test Limitations: Non-specific for infection stage; clinical correlation is needed. Sample quality affects sensitivity.
References: CDC West Nile Virus Guidelines, 2023; Clinical Infectious Diseases, Nash D, 2022.
